<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241204111435&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241204111435&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 04 Dec 2024 16:14:36 +0000</lastbuilddate>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TCF21 expression is not required to maintain the cell state of CFs in the adult heart. However, preventing the normal downregulation of TCF21 expression with injury reduces myofibroblast formation, cardiac fibrosis, and the acute cardiac hypertrophic response following 1 week of Ang II/phenylephrine stimulation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325527. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the embryonic heart. In the adult heart, TCF21 is expressed in tissue-resident fibroblasts and is downregulated in response to injury or stimuli leading to myofibroblast differentiation. These findings led to the hypothesis that TCF21 regulates fibroblast differentiation in the adult mammalian heart to affect fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Tamoxifen-inducible Cre genetic mouse models were used to permit either <i>Tcf21</i> gene deletion or its enforced expression in adult CFs. Histological and echocardiographic analyses were used, as well as transcriptomic analysis to determine the consequences of TCF21 gain-of-function and loss-of-function in vivo. Genomic <i>Tcf21</i> occupancy was identified by chromatin immunoprecipitation and sequencing in CFs. Myocardial infarction and Ang II (angiotensin II)/phenylephrine served as models of cardiac fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Acute and long-term deletion of <i>Tcf21</i> in CFs of the adult mouse heart does not alter fibroblast numbers, myofibroblast differentiation, or fibrosis. Fibroblast-specific <i>Tcf21</i> gene-deleted mice demonstrate no significant alterations in cardiac function or scar formation in response to cardiac injury compared with control mice. In contrast, enforced expression of TCF21 in CFs inhibits myofibroblast differentiation and significantly reduces cardiac fibrosis and hypertrophy in response to 1 week of Ang II/phenylephrine infusion. Mechanistically, sustained TCF21 expression prevents the induction of genes associated with fibrosis and ECM (extracellular matrix) organization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TCF21 expression is not required to maintain the cell state of CFs in the adult heart. However, preventing the normal downregulation of TCF21 expression with injury reduces myofibroblast formation, cardiac fibrosis, and the acute cardiac hypertrophic response following 1 week of Ang II/phenylephrine stimulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39629593</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325527>10.1161/CIRCRESAHA.124.325527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629593</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Anne Katrine Z Johansen</dc:creator>
<dc:creator>Rajesh K Kasam</dc:creator>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:creator>Suh-Chin J Lin</dc:creator>
<dc:creator>Jose G Gomez-Arroyo</dc:creator>
<dc:creator>Adenike Shittu</dc:creator>
<dc:creator>Stephanie L K Bowers</dc:creator>
<dc:creator>Yasuhide Kuwabara</dc:creator>
<dc:creator>Kelly M Grimes</dc:creator>
<dc:creator>Kathrynne Warrick</dc:creator>
<dc:creator>Michelle A Sargent</dc:creator>
<dc:creator>Tanya A Baldwin</dc:creator>
<dc:creator>Susan E Quaggin</dc:creator>
<dc:creator>Artem Barski</dc:creator>
<dc:creator>Jeffery D Molkentin</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis</dc:title>
<dc:identifier>pmid:39629593</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325527</dc:identifier>
</item>
<item>
<title>A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study demonstrates the FAP vaccine can be a therapeutic tool for cardiac fibrosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myofibroblasts are primary cells involved in chronic response-induced cardiac fibrosis. Fibroblast activation protein (FAP) is a relatively specific marker of activated myofibroblasts and a potential target molecule. This study aimed to clarify whether a vaccine targeting FAP could eliminate myofibroblasts in chronic cardiac stress model mice and reduce cardiac fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We coadministered a FAP peptide vaccine with a CpG K3 oligonucleotide adjuvant to male C57/BL6J mice and confirmed an elevation in the anti-FAP antibody titer. After continuous angiotensin II and phenylephrine administration for 28 days, we evaluated the degree of cardiac fibrosis and the number of myofibroblasts in cardiac tissues.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that cardiac fibrosis was significantly decreased in the FAP-vaccinated mice compared with the angiotensin II and phenylephrine control mice (3.45±1.11% versus 8.62±4.79%; <i>P</i>=4.59×10<sup>-3</sup>) and that the accumulation of FAP-positive cells was also significantly decreased, as indicated by FAP immunohistochemical staining (4077±1746 versus 7327±1741 cells/mm<sup>2</sup>; FAP vaccine versus angiotensin II and phenylephrine control; <i>P</i>=6.67×10<sup>-</sup><sup>3</sup>). No systemic or organ-specific inflammation due to antibody-dependent cell cytotoxicity induced by the FAP vaccine was observed. Although the transient activation of myofibroblasts has an important role in maintaining the structural robustness in the process of tissue repair, the FAP vaccine showed no adverse effects in myocardial infarction and skin injury models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates the FAP vaccine can be a therapeutic tool for cardiac fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39629565</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325017>10.1161/CIRCRESAHA.124.325017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629565</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shota Yoshida</dc:creator>
<dc:creator>Hiroki Hayashi</dc:creator>
<dc:creator>Takuro Kawahara</dc:creator>
<dc:creator>Shunsuke Katsuki</dc:creator>
<dc:creator>Mitsukuni Kimura</dc:creator>
<dc:creator>Rissei Hino</dc:creator>
<dc:creator>Jiao Sun</dc:creator>
<dc:creator>Ryo Nakamaru</dc:creator>
<dc:creator>Akiko Tenma</dc:creator>
<dc:creator>Masayoshi Toyoura</dc:creator>
<dc:creator>Satoshi Baba</dc:creator>
<dc:creator>Munehisa Shimamura</dc:creator>
<dc:creator>Tomohiro Katsuya</dc:creator>
<dc:creator>Ryuichi Morishita</dc:creator>
<dc:creator>Hiromi Rakugi</dc:creator>
<dc:creator>Tetsuya Matoba</dc:creator>
<dc:creator>Hironori Nakagami</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts</dc:title>
<dc:identifier>pmid:39629565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325017</dc:identifier>
</item>
<item>
<title>Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We demonstrate that PO-HF is triggered by hemodynamic stress and then sets off an autoimmune-like response against cardiac self-antigens. The antigens can be used to reduce the severity of future-onset disease, via oral tolerization, effectively acting as a protective vaccine.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.324999. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is strongly associated with inflammation. In pressure overload (PO)-induced HF, cardiac stress triggers adaptive immunity, ablation, or inhibition, which blocks disease progression. We hypothesized that PO-HF might fulfill the often-used criteria of autoimmunity: if so, the associated adaptive immune response would be not only necessary but also sufficient to induce HF; it should also be possible to identify self-antigens driving the autoimmune response. Finally, we hypothesized that such an antigen-specific response can be manipulated to preventively reduce the severity of PO-HF in a tolerizing vaccine.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used the transfer of lymphocytes or serum from PO-HF mice into healthy recipients to assess whether the adaptive response is sufficient to induce disease. We devised a novel pipeline to identify self-antigens driving the response. We immunized healthy mice with novel antigens to assess whether they induce disease. To determine whether these antigens could be present in human patients, we sought to detect existing responses against these antigens in patients with HF. Finally, we used the antigens in an oral tolerance protocol to preventively protect mice from subsequently induced PO-HF, analyzing the results with next-generation sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that PO-HF fulfills the criteria of an autoimmune disease, albeit partially, and identified novel cardiac self-antigens, capable of inducing cardiac dysfunction. The novel antigens in a tolerizing vaccine formulation preemptively reduced the severity of disease triggered by subsequent application of PO, via induction of effector regulatory T cells, enabling a potent reduction of PO-driven loss of systolic function, cardiac inflammation, and proinflammatory CD4<sup>+</sup> T-cell clonal expansion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We demonstrate that PO-HF is triggered by hemodynamic stress and then sets off an autoimmune-like response against cardiac self-antigens. The antigens can be used to reduce the severity of future-onset disease, via oral tolerization, effectively acting as a protective vaccine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39629560</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324999>10.1161/CIRCRESAHA.124.324999</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629560</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Elisa Martini</dc:creator>
<dc:creator>Marco Cremonesi</dc:creator>
<dc:creator>Arianna Felicetta</dc:creator>
<dc:creator>Simone Serio</dc:creator>
<dc:creator>Simone Puccio</dc:creator>
<dc:creator>Erica Pelamatti</dc:creator>
<dc:creator>Jasper J P van Beek</dc:creator>
<dc:creator>Vasiliki Papadopoulou</dc:creator>
<dc:creator>Chiara Catalano</dc:creator>
<dc:creator>Francesca Fanuele</dc:creator>
<dc:creator>Desirée Giuliano</dc:creator>
<dc:creator>Gianluca Basso</dc:creator>
<dc:creator>Cecilia Assunta Bonfiglio</dc:creator>
<dc:creator>Cristina Panico</dc:creator>
<dc:creator>Marco Vacchiano</dc:creator>
<dc:creator>Pierluigi Carullo</dc:creator>
<dc:creator>Laura Papa</dc:creator>
<dc:creator>Carla D'Andrea</dc:creator>
<dc:creator>Naz Tuzger</dc:creator>
<dc:creator>Sergio Marchini</dc:creator>
<dc:creator>Paola Magistroni</dc:creator>
<dc:creator>Silvia Deaglio</dc:creator>
<dc:creator>Antonio Amoroso</dc:creator>
<dc:creator>Enrico Lugli</dc:creator>
<dc:creator>Gianluigi Condorelli</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy</dc:title>
<dc:identifier>pmid:39629560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324999</dc:identifier>
</item>
<item>
<title>GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Deletion of GSK3β in adipocytes activates the AMPK/HIF-2α/VEGF/VEGFR2 axis, promoting vasculature expansion within obese AT. This results in a significantly improved local microenvironment, reducing inflammation and effectively ameliorating metabolic disorders associated with obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325187. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Maintaining a well-developed vascular system alongside adipose tissue (AT) expansion significantly reduces the risk of metabolic complications. Although GSK3β (glycogen synthase kinase-3 beta) is known for its role in various cellular processes, its specific functions in AT and regulation of body homeostasis have not been reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: GSK3β-floxed and GSK3α-floxed mice were crossed with adiponectin-Cre mice to generate GSK3β or GSK3α adipocyte-specific knockout mice (GSK3β<sup>ADKO</sup> and GSK3α<sup>ADKO</sup>). A comprehensive whole-body metabolism analysis was performed on obese GSK3β<sup>ADKO</sup> mice induced by a high-fat diet. RNA sequencing was conducted on AT of both obese GSK3β<sup>ADKO</sup> and GSK3α<sup>ADKO</sup> mice. Various analyses, including vessel perfusion studies, lipolysis analysis, multiplex protein assays, in vitro protein phosphorylation assays, and whole-mount histology staining, were performed on AT of obese GSK3β<sup>ADKO</sup> mice. Tube-formation experiments were performed using 3B-11 endothelial cells cultured in the conditional medium of matured adipocytes under hypoxic conditions. Chromatin precipitation and immunofluorescence studies were conducted using cultured adipocytes with GSK3 inhibition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our findings provide the first evidence that adipocyte-specific knockout of GSK3β expands AT vascularization and mitigates obesity-related metabolic disorders. GSK3β deficiency, but not GSK3α, in adipocytes activates AMPK (AMP-activated protein kinase), leading to increased phosphorylation and nuclear accumulation of HIF-2α, resulting in enhanced transcriptional regulation. Consequently, adipocytes increased VEGF (vascular endothelial growth factor) expression, which engages VEGFR2 on endothelial cells, promoting angiogenesis, expanding the vasculature, and improving vessel perfusion within obese AT. GSK3β deficiency promotes AT remodeling, shifting unhealthy adipocyte function toward a healthier state by increasing insulin-sensitizing hormone adiponectin and preserving healthy adipocyte function. These effects lead to reduced fibrosis, reactive oxygen species, and ER stress in obese AT and improve metabolic disorders associated with obesity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Deletion of GSK3β in adipocytes activates the AMPK/HIF-2α/VEGF/VEGFR2 axis, promoting vasculature expansion within obese AT. This results in a significantly improved local microenvironment, reducing inflammation and effectively ameliorating metabolic disorders associated with obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39629559</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325187>10.1161/CIRCRESAHA.124.325187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629559</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Jiajia Li</dc:creator>
<dc:creator>Ping Tang</dc:creator>
<dc:creator>Dongliang Zhu</dc:creator>
<dc:creator>Lixin Tai</dc:creator>
<dc:creator>Yuan Wang</dc:creator>
<dc:creator>Tsukiko Miyata</dc:creator>
<dc:creator>James R Woodgett</dc:creator>
<dc:creator>Lijun Di</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders</dc:title>
<dc:identifier>pmid:39629559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325187</dc:identifier>
</item>
<item>
<title>Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>The mammalian pancreas consists of three epithelial compartments: the acini and ducts of the exocrine pancreas and the endocrine islets of Langerhans. Murine studies indicate that these three compartments derive from a transient, common pancreatic progenitor. Here, we report derivation of 18 human fetal pancreas organoid (hfPO) lines from gestational weeks 8-17 (8-17 GWs) fetal pancreas samples. Four of these lines, derived from 15 to 16 GWs samples, generate acinar-, ductal-, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 2:S0092-8674(24)01254-6. doi: 10.1016/j.cell.2024.10.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The mammalian pancreas consists of three epithelial compartments: the acini and ducts of the exocrine pancreas and the endocrine islets of Langerhans. Murine studies indicate that these three compartments derive from a transient, common pancreatic progenitor. Here, we report derivation of 18 human fetal pancreas organoid (hfPO) lines from gestational weeks 8-17 (8-17 GWs) fetal pancreas samples. Four of these lines, derived from 15 to 16 GWs samples, generate acinar-, ductal-, and endocrine-lineage cells while expanding exponentially for >;2 years under optimized culture conditions. Single-cell RNA sequencing identifies rare LGR5<sup>+</sup> cells in fetal pancreas and in hfPOs as the root of the developmental hierarchy. These LGR5<sup>+</sup> cells share multiple markers with adult gastrointestinal tract stem cells. Organoids derived from single LGR5<sup>+</sup> organoid-derived cells recapitulate this tripotency in vitro. We describe a human fetal tripotent stem/progenitor cell capable of long-term expansion in vitro and of generating all three pancreatic cell lineages.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39626658</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.044>10.1016/j.cell.2024.10.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626658</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Amanda Andersson-Rolf</dc:creator>
<dc:creator>Kelvin Groot</dc:creator>
<dc:creator>Jeroen Korving</dc:creator>
<dc:creator>Harry Begthel</dc:creator>
<dc:creator>Maaike A J Hanegraaf</dc:creator>
<dc:creator>Michael VanInsberghe</dc:creator>
<dc:creator>Fredrik Salmén</dc:creator>
<dc:creator>Stieneke van den Brink</dc:creator>
<dc:creator>Carmen Lopez-Iglesias</dc:creator>
<dc:creator>Peter J Peters</dc:creator>
<dc:creator>Daniel Krueger</dc:creator>
<dc:creator>Joep Beumer</dc:creator>
<dc:creator>Maarten H Geurts</dc:creator>
<dc:creator>Anna Alemany</dc:creator>
<dc:creator>Helmuth Gehart</dc:creator>
<dc:creator>Françoise Carlotti</dc:creator>
<dc:creator>Eelco J P de Koning</dc:creator>
<dc:creator>Susana M Chuva de Sousa Lopes</dc:creator>
<dc:creator>Alexander van Oudenaarden</dc:creator>
<dc:creator>Johan H van Es</dc:creator>
<dc:creator>Hans Clevers</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages</dc:title>
<dc:identifier>pmid:39626658</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.044</dc:identifier>
</item>
<item>
<title>Artificial intelligence-derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The AI-derived ECG aging was associated with the risk of new- and early-onset AF, suggesting its potential utility to identify individuals for AF prevention across diverse populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae790. doi: 10.1093/eurheartj/ehae790. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Artificial intelligence (AI) algorithms in 12-lead electrocardiogram (ECG) provides promising age prediction methods. This study investigated whether the discrepancy between ECG-derived AI-predicted age (AI-ECG age) and chronological age, termed electrocardiographic aging (ECG aging), is associated with atrial fibrillation (AF) risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An AI-ECG age prediction model was developed using a large-scale dataset (1 533 042 ECGs from 689 639 participants) and validated with six independent and multi-national datasets (737 133 ECGs from 330 794 participants). The AI-ECG age gap was calculated across two South Korean cohorts [mean (standard deviation) follow-up: 4.1 (4.3) years for 111 483 participants and 6.1 (3.8) years for 37 517 participants], one UK cohort [3.0 (1.6) years; 40 973 participants], and one US cohort [12.9 (8.6) years; 90 639 participants]. Participants were classified into two groups: normal group (age gap &lt; 7 years) and ECG-aged group (age gap ≥ 7 years). The predictive capability of ECG aging for new- and early-onset AF risk was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean AI-ECG ages were 51.9 (16.2), 47.4 (12.5), 68.4 (7.8), and 56.7 (14.6) years with age gaps of .0 (6.8), -.1 (6.0), 4.7 (8.7), and -1.4 (8.9) years in the two South Korean, UK, and US cohorts, respectively. In the ECG-aged group, increased risks of new-onset AF were observed with hazard ratios (95% confidence intervals) of 2.50 (2.24-2.78), 1.89 (1.46-2.43), 1.90 (1.55-2.33), and 1.76 (1.67-1.86) in the two South Korean, UK, and US cohorts, respectively. For early-onset AF, odds ratios were 2.89 (2.47-3.37), 1.94 (1.39-2.70), 1.58 (1.06-2.35), and 1.79 (1.62-1.97) in these cohorts compared with the normal group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The AI-derived ECG aging was associated with the risk of new- and early-onset AF, suggesting its potential utility to identify individuals for AF prevention across diverse populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39626169</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae790>10.1093/eurheartj/ehae790</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626169</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Seunghoon Cho</dc:creator>
<dc:creator>Sujeong Eom</dc:creator>
<dc:creator>Daehoon Kim</dc:creator>
<dc:creator>Tae-Hoon Kim</dc:creator>
<dc:creator>Jae-Sun Uhm</dc:creator>
<dc:creator>Hui-Nam Pak</dc:creator>
<dc:creator>Moon-Hyoung Lee</dc:creator>
<dc:creator>Pil-Sung Yang</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Zachi Itzhak Attia</dc:creator>
<dc:creator>Paul Andrew Friedman</dc:creator>
<dc:creator>Seng Chan You</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Boyoung Joung</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study</dc:title>
<dc:identifier>pmid:39626169</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae790</dc:identifier>
</item>
<item>
<title>Artificial intelligence and digital tools for design and execution of cardiovascular clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials. Advances in domain tasks such as automated diagnosis and classification, synthesis of high-volume data and latent data from adjacent modalities, patient discovery, telemedicine, remote monitoring, augmented reality, and in silico modelling have the potential to enhance the efficiency, accuracy, and cost-effectiveness of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae794. doi: 10.1093/eurheartj/ehae794. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials. Advances in domain tasks such as automated diagnosis and classification, synthesis of high-volume data and latent data from adjacent modalities, patient discovery, telemedicine, remote monitoring, augmented reality, and in silico modelling have the potential to enhance the efficiency, accuracy, and cost-effectiveness of cardiovascular clinical trials. However, early experience with these tools has also exposed important issues, including regulatory barriers, clinical validation and acceptance, technological literacy, integration with care models, and health equity concerns. This narrative review summarizes the landscape of digital tools at each stage of clinical trial planning and execution and outlines roadblocks and opportunities for successful implementation of digital tools in cardiovascular clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39626166</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae794>10.1093/eurheartj/ehae794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626166</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jiun-Ruey Hu</dc:creator>
<dc:creator>John R Power</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence and digital tools for design and execution of cardiovascular clinical trials</dc:title>
<dc:identifier>pmid:39626166</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae794</dc:identifier>
</item>
<item>
<title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3. doi: 10.1161/CIR.0000000000001293. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine products has transformed since the last American Heart Association smokeless tobacco policy statement. Several varieties of tobacco-free oral nicotine products-including oral nicotine pouches; nontherapeutic nicotine gums, lozenges, and tablets; and nicotine gummies-have rapidly proliferated. The sales of oral nicotine pouches, in particular, have increased substantially; however, no data are available on their cardiovascular or health risks. In addition, synthetic (compared with tobacco-derived) nicotine has been used in some brands of oral nicotine products, but its cardiovascular and health effects have been inadequately studied. Robust public policy levers are identified to support ending addiction to all commercial tobacco products. Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39624904</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001293>10.1161/CIR.0000000000001293</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39624904</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Cheryl R Dennison Himmelfarb</dc:creator>
<dc:creator>Neal L Benowitz</dc:creator>
<dc:creator>Melissa D Blank</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Paul J Chase</dc:creator>
<dc:creator>Esa M Davis</dc:creator>
<dc:creator>Jessica L Fetterman</dc:creator>
<dc:creator>Brittney Keller-Hamilton</dc:creator>
<dc:creator>Oluwabunmi Ogungbe</dc:creator>
<dc:creator>Robert L Page</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Rose Marie Robertson</dc:creator>
<dc:creator>Laurie P Whitsel</dc:creator>
<dc:creator>American Heart Association Advocacy Coordinating Committee</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39624904</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001293</dc:identifier>
</item>
<item>
<title>Long-QT Trafficking Map</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1882-1884. doi: 10.1161/CIRCULATIONAHA.124.072169. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621763</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11614379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">PMC11614379</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072169>10.1161/CIRCULATIONAHA.124.072169</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621763</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Barry London</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-QT Trafficking Map</dc:title>
<dc:identifier>pmid:39621763</dc:identifier>
<dc:identifier>pmc:PMC11614379</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072169</dc:identifier>
</item>
<item>
<title>In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>Conventional forms of noninvasive cardiovascular imaging that evaluate morphology, function, flow, and metabolism play a vital role in individual treatment decisions, often based on guidelines. Innovations in molecular imaging have enhanced our ability to spatially quantify the expression of a wider array of disease-related proteins, genes, or cell types, or the activity of specific pathogenic pathways. These techniques, which usually rely on design of targeted imaging probes, have already been...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1885-1897. doi: 10.1161/CIRCULATIONAHA.124.066522. Epub 2024 Dec 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Conventional forms of noninvasive cardiovascular imaging that evaluate morphology, function, flow, and metabolism play a vital role in individual treatment decisions, often based on guidelines. Innovations in molecular imaging have enhanced our ability to spatially quantify the expression of a wider array of disease-related proteins, genes, or cell types, or the activity of specific pathogenic pathways. These techniques, which usually rely on design of targeted imaging probes, have already been used extensively in cancer medicine and have now become part of cardiovascular care in conditions such as amyloidosis and sarcoidosis. The recognition that common cardiovascular conditions are caused by a substantial diversity of pathobiologic pathways and the diversity of therapies available for use have rekindled interest in expanding the role of molecular imaging of tissue phenotype to improve precision in diagnosis and therapeutic decision-making. The intent of this article is to raise awareness and understanding of approaches to molecular or cellular imaging of phenotype with targeted probes, and their potential to promote the principles of precision medicine. Also addressed are the diverse roles of molecular imaging to improve precision and efficiency of new drug development at the stages of candidate identification, preclinical testing, and clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621762</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.066522>10.1161/CIRCULATIONAHA.124.066522</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621762</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan R Lindner</dc:creator>
<dc:creator>Matteo Morello</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development</dc:title>
<dc:identifier>pmid:39621762</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.066522</dc:identifier>
</item>
<item>
<title>Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621761/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):e468. doi: 10.1161/CIRCULATIONAHA.124.070892. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621761/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621761</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070892>10.1161/CIRCULATIONAHA.124.070892</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621761</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Xinyue Yang</dc:creator>
<dc:creator>Zhiqiang Zhang</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</dc:title>
<dc:identifier>pmid:39621761</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070892</dc:identifier>
</item>
<item>
<title>Echocardiography, the AHA, and 100 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1819-1822. doi: 10.1161/CIRCULATIONAHA.124.066991. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621760</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.066991>10.1161/CIRCULATIONAHA.124.066991</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621760</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Joseph Kisslo</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Echocardiography, the AHA, and 100 Years</dc:title>
<dc:identifier>pmid:39621760</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.066991</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1898-1903. doi: 10.1161/CIRCULATIONAHA.124.072974. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621759</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072974>10.1161/CIRCULATIONAHA.124.072974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621759</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39621759</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072974</dc:identifier>
</item>
<item>
<title>Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):e469-e470. doi: 10.1161/CIRCULATIONAHA.124.071539. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621758</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071539>10.1161/CIRCULATIONAHA.124.071539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621758</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</dc:title>
<dc:identifier>pmid:39621758</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071539</dc:identifier>
</item>
<item>
<title>Pitfalls of Choosing a Study End Point Including Cardiovascular Death in Comparative Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1823-1825. doi: 10.1161/CIRCULATIONAHA.124.070899. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39621757</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070899>10.1161/CIRCULATIONAHA.124.070899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621757</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephanie Armbruster</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Lee-Jen Wei</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pitfalls of Choosing a Study End Point Including Cardiovascular Death in Comparative Clinical Trials</dc:title>
<dc:identifier>pmid:39621757</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070899</dc:identifier>
</item>
<item>
<title>Data science from EuroHeart: a job in hand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae819. doi: 10.1093/eurheartj/ehae819. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39612912</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae819>10.1093/eurheartj/ehae819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39612912</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Timmis</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Data science from EuroHeart: a job in hand</dc:title>
<dc:identifier>pmid:39612912</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae819</dc:identifier>
</item>
<item>
<title>Proteolethargy is a pathogenic mechanism in chronic disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 25:S0092-8674(24)01274-1. doi: 10.1016/j.cell.2024.10.051. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was linked to cysteine residues in the affected proteins and signaling-related increases in excess reactive oxygen species. Diverse pathogenic stimuli, including hyperglycemia, dyslipidemia, and inflammation, produce similar reduced protein mobility phenotypes. We propose that proteolethargy is an overlooked cellular mechanism that may account for various pathogenic features of diverse chronic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39610243</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.051>10.1016/j.cell.2024.10.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39610243</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alessandra Dall'Agnese</dc:creator>
<dc:creator>Ming M Zheng</dc:creator>
<dc:creator>Shannon Moreno</dc:creator>
<dc:creator>Jesse M Platt</dc:creator>
<dc:creator>An T Hoang</dc:creator>
<dc:creator>Deepti Kannan</dc:creator>
<dc:creator>Giuseppe Dall'Agnese</dc:creator>
<dc:creator>Kalon J Overholt</dc:creator>
<dc:creator>Ido Sagi</dc:creator>
<dc:creator>Nancy M Hannett</dc:creator>
<dc:creator>Hailey Erb</dc:creator>
<dc:creator>Olivia Corradin</dc:creator>
<dc:creator>Arup K Chakraborty</dc:creator>
<dc:creator>Tong Ihn Lee</dc:creator>
<dc:creator>Richard A Young</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Proteolethargy is a pathogenic mechanism in chronic disease</dc:title>
<dc:identifier>pmid:39610243</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.051</dc:identifier>
</item>
<item>
<title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae623. doi: 10.1093/eurheartj/ehae623. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39607800</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae623>10.1093/eurheartj/ehae623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607800</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Angelo Oliva</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</dc:title>
<dc:identifier>pmid:39607800</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae623</dc:identifier>
</item>
<item>
<title>Acetylation alchemy: how Nat10 shapes vascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae822. doi: 10.1093/eurheartj/ehae822. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39607798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae822>10.1093/eurheartj/ehae822</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607798</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Timothy Warwick</dc:creator>
<dc:creator>Leo Kurian</dc:creator>
<dc:creator>Ralf P Brandes</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acetylation alchemy: how Nat10 shapes vascular health</dc:title>
<dc:identifier>pmid:39607798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae822</dc:identifier>
</item>
<item>
<title>Thoracic aortic disease: why sex matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae713. doi: 10.1093/eurheartj/ehae713. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39607796</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae713>10.1093/eurheartj/ehae713</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607796</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Julia Dumfarth</dc:creator>
<dc:creator>Simone Gasser</dc:creator>
<dc:creator>Michael Grimm</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thoracic aortic disease: why sex matters</dc:title>
<dc:identifier>pmid:39607796</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae713</dc:identifier>
</item>
<item>
<title>Pregnancy-related aortic pathology: where do we go from here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241204111435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae697. doi: 10.1093/eurheartj/ehae697. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241204111435&v=2.18.0.post9+e462414">39607795</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae697>10.1093/eurheartj/ehae697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607795</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Johanna A van der Zande</dc:creator>
<dc:creator>Mark R Johnson</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pregnancy-related aortic pathology: where do we go from here?</dc:title>
<dc:identifier>pmid:39607795</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae697</dc:identifier>
</item>





























</channel>
</rss>